Hypertrophic non-union of the first rib causing thoracic outlet syndrome: a case report.

por Suh, J. T., Park, B. G., Yoo, C. I.
Publicado 2001

Isoniazid resistance and the point mutation of codon 463 of katG gene of Mycobacterium tuberculosis.

por Shim, T. S., Yoo, C. G., Han, S. K., Shim, Y. S., Kim, Y. W.
Publicado 1997

Growth of Ovarian Primary Follicles Retrieved from Neonates of Different Ages and Derivation of Mature Oocytes Following In vitro-Culture

por Choi, J. H., Yoo, C. R., Ahn, J. Y., Park, J. H., Lim, J. M.
Publicado 2012

The clinical characteristics of pulmonary alveolar proteinosis: experience at Seoul National University Hospital, and review of the literature.

por Kim, G., Lee, S. J., Lee, H. P., Yoo, C. G., Han, S. K., Shim, Y. S., Kim, Y. W.
Publicado 1999

Phase Angle and Frailty are Important Prognostic Factors in Critically Ill Medical Patients: A Prospective Cohort Study

por Ko, S. J., Cho, J., Choi, S. M., Park, Y. S., Lee, C.-H., Lee, S.-M., Yoo, C.-G., Kim, Y. W., Lee, Jinwoo
Publicado 2020

Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study

por Jeong, H., Shin, J., Jeong, J.H., Kim, K.-p., Hong, S.-M., Kim, Y.-i., Ryu, J.-S., Ryoo, B.-Y., Yoo, C.
Publicado 2021

The Possibility of TBC1D21 as a Candidate Gene for Teat Numbers in Pigs

por Jin, S., Lee, J. B., Kang, K., Yoo, C. K., Kim, B. M., Park, H. B., Lim, H. T., Cho, I. C., Maharani, D., Lee, J. H.
Publicado 2013

Redox signalling to nuclear regulatory proteins by reactive oxygen species contributes to oestrogen-induced growth of breast cancer cells

por Okoh, V O, Garba, N A, Penney, R B, Das, J, Deoraj, A, Singh, K P, Sarkar, S, Felty, Q, Yoo, C, Jackson, R M, Roy, D
Publicado 2015

Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib

por Kang, Y-K, Yoo, C, Ryoo, B-Y, Lee, J J, Tan, E, Park, I, Park, J H, Choi, Y J, Jo, J, Ryu, J-S, Ryu, M-H
Publicado 2013

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer

por Yoo, C, Hwang, J Y, Kim, J-E, Kim, T W, Lee, J S, Park, D H, Lee, S S, Seo, D W, Lee, S K, Kim, M-H, Han, D J, Kim, S C, Lee, J-L
Publicado 2009

Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX

por Hyung, J., Lee, H., Jin, H., Lee, S., Lee, H.J., Gong, G., Song, T.J., Lee, S.S., Hwang, D.W., Kim, S.C., Jeong, J.H., Ryoo, B.-Y., Kim, K., Yoo, C.
Publicado 2022

Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase...

por Hyung, J., Lee, J.Y., Kim, J.E., Yoon, S., Yoo, C., Hong, Y.S., Jeong, J.H., Kim, T.W., Jeon, S., Jun, H.R., Jung, C.K., Jang, J.P., Kim, J., Chun, S.M., Ahn, J.H.
Publicado 2023

Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective stud...

por Park, H.S., Kang, B., Chon, H.J., Im, H.-S., Lee, C.-K., Kim, I., Kang, M.J., Hwang, J.E., Bae, W.K., Cheon, J., Park, J.O., Hong, J.Y., Kang, J.H., Kim, J.H., Lim, S.H., Kim, J.W., Kim, J.-W., Yoo, C., Choi, H.J.
Publicado 2021

Novel experimental setup for megahertz X-ray diffraction in a diamond anvil cell at the High Energy Density (HED) instrument of the European X-ray Free-Electron Laser (EuXFEL)

por Liermann, H. P., Konôpková, Z., Appel, K., Prescher, C., Schropp, A., Cerantola, V., Husband, R. J., McHardy, J. D., McMahon, M. I., McWilliams, R. S., Pépin, C. M., Mainberger, J., Roeper, M., Berghäuser, A., Damker, H., Talkovski, P., Foese, M., Kujala, N., Ball, O. B., Baron, M. A., Briggs, R., Bykov, M., Bykova, E., Chantel, J., Coleman, A. L., Cynn, H., Dattelbaum, D., Dresselhaus-Marais, L. E., Eggert, J. H., Ehm, L., Evans, W. J., Fiquet, G., Frost, M., Glazyrin, K., Goncharov, A. F., Hwang, H., Jenei, Zs., Kim, J.-Y., Langenhorst, F., Lee, Y., Makita, M., Marquardt, H., McBride, E. E., Merkel, S., Morard, G., O’Bannon, E. F., Otzen, C., Pace, E. J., Pelka, A., Pigott, J. S., Prakapenka, V. B., Redmer, R., Sanchez-Valle, C., Schoelmerich, M., Speziale, S., Spiekermann, G., Sturtevant, B. T., Toleikis, S., Velisavljevic, N., Wilke, M., Yoo, C.-S., Baehtz, C., Zastrau, U., Strohm, C.
Publicado 2021

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

por Rimini, M., Rimassa, L., Ueshima, K., Burgio, V., Shigeo, S., Tada, T., Suda, G., Yoo, C., Cheon, J., Pinato, D.J., Lonardi, S., Scartozzi, M., Iavarone, M., Di Costanzo, G.G., Marra, F., Soldà, C., Tamburini, E., Piscaglia, F., Masi, G., Cabibbo, G., Foschi, F.G., Silletta, M., Pressiani, T., Nishida, N., Iwamoto, H., Sakamoto, N., Ryoo, B.-Y., Chon, H.J., Claudia, F., Niizeki, T., Sho, T., Kang, B., D’Alessio, A., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Ochi, H., Yasuda, S., Toyoda, H., Ogawa, C., Nishimur, T., Hatanaka, T., Kakizaki, S., Shimada, N., Kawata, K., Tanaka, T., Ohama, H., Nouso, K., Morishita, A., Tsutsui, A., Nagano, T., Itokawa, N., Okubo, T., Arai, T., Imai, M., Naganuma, A., Koizumi, Y., Nakamura, S., Joko, K., Iijima, H., Hiasa, Y., Pedica, F., De Cobelli, F., Ratti, F., Aldrighetti, L., Kudo, M., Cascinu, S., Casadei-Gardini, A.
Publicado 2022